<h1 id="fibrinolysis-for-acute-pulmonary-embolism-pe-">Fibrinolysis for Acute Pulmonary Embolism (PE)</h1>
<p><strong>Massive PE:</strong> Acute PE with at least 1 of the following:</p>
<ul>
<li>Sustained hypotension from PE itself (SBP &lt; 90 mmHg for ≥ 15 min, or requiring inotropic support)</li>
<li>Pulselessness</li>
<li>Persistent profound bradycardia (HR &lt; 40 bpm with signs/symptoms of shock)</li>
</ul>
<p><strong>Submassive PE:</strong> Acute PE without systemic hypotension (SBP ≥ 90 mmHg) but with either RV dysfunction or myocardial necrosis.</p>
<ul>
<li><p><em>RV dysfunction:</em> the presence of at least 1 of the following:</p>
<ul>
<li>Echo: RV dilation (apical 4-chamber RV diameter divided by LV diameter &gt; 0.9), or RV systolic dysfunction</li>
<li>CT: RV dilation (4-chamber RV diameter divided by LV diameter &gt; 0.9)</li>
<li>BNP &gt; 90 pg/mL</li>
<li>N-terminal pro-BNP &gt; 500 pg/mL</li>
<li>ECG changes: New complete or incomplete right BBB, anteroseptal ST elevation or depression, or anteroseptal T-wave inversion</li>
</ul>
</li>
<li><p><em>Myocardial necrosis is defined as either of the following</em>:</p>
<ul>
<li>Troponin I &gt; 0.4 ng/mL</li>
<li>Troponin T &gt; 0.1 ng/mL</li>
</ul>
</li>
</ul>
<p><strong>Low Risk PE</strong>: Acute PE and the absence of clinical markers of adverse prognosis that define massive or submassive PE</p>
<h2 id="fibrinolysis-recommendations">Fibrinolysis Recommendations</h2>
<table>
<colgroup>
<col width="50%" />
<col width="50%" />
</colgroup>
<tbody>
<tr class="odd">
<td>Reasonable to give:</td>
<td>Massive acute PE and acceptable risk of bleeding complications.</td>
</tr>
<tr class="even">
<td>Consider giving it:</td>
<td>Submassive acute PE with clinical evidence of adverse prognosis (new hemodynamic instability, worsening respiratory insufficiency, severe RV dysfunction, or major myocardial necrosis) and low risk of bleeding complications.</td>
</tr>
<tr class="odd">
<td>Not recommended:</td>
<td><ul>
<li>Low-risk PE</li>
<li>Submassive acute PE with minor RV dysfunction, minor myocardial necrosis, and no clinical worsening</li>
<li>Undifferentiated cardiac arrest</li>
</ul></td>
</tr>
</tbody>
</table>

<h2 id="fibrinolytic-dosing">Fibrinolytic dosing</h2>
<p><strong>Alteplase</strong> 100 mg IV over 2 hours.</p>
<ul>
<li>Consider contraindications for Alteplase when deciding to proceed with Rx</li>
<li>Currently, only FDA approved agents for PE are urokinase, streptokinase, and alteplase. Tenecteplase studies in progress.</li>
</ul>
<h2 id="references">References</h2>
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23102885">Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M; “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the &quot;MOPETT&quot; Trial). Am J Cardiol. 2013 Jan 15;111(2):273-7.</a></li>
<li><a href="http://circ.ahajournals.org/content/123/16/1788.full">Jaff MR et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary HTN. Circulation. 2011;123(16):1788-830.</a></li>
</ul>
